<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/354610BC-CCBE-43F3-8DD6-BB675FC6E62B"><gtr:id>354610BC-CCBE-43F3-8DD6-BB675FC6E62B</gtr:id><gtr:name>Chiba University</gtr:name><gtr:address><gtr:line1>Chiba University</gtr:line1><gtr:line2>1-33, Yayoi-cho</gtr:line2><gtr:line4>Inage-Ku</gtr:line4><gtr:line5>Chiba-shi</gtr:line5><gtr:postCode>263-8522</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Centre for Molecular Medicine</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C687B40-4780-4290-A0E0-39EC669D33CF"><gtr:id>9C687B40-4780-4290-A0E0-39EC669D33CF</gtr:id><gtr:name>Muhimbili University of Health and Allied Sciences</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/354610BC-CCBE-43F3-8DD6-BB675FC6E62B"><gtr:id>354610BC-CCBE-43F3-8DD6-BB675FC6E62B</gtr:id><gtr:name>Chiba University</gtr:name><gtr:address><gtr:line1>Chiba University</gtr:line1><gtr:line2>1-33, Yayoi-cho</gtr:line2><gtr:line4>Inage-Ku</gtr:line4><gtr:line5>Chiba-shi</gtr:line5><gtr:postCode>263-8522</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Japan</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/518FB5B4-0267-4CA1-A7E0-F90E0D09022E"><gtr:id>518FB5B4-0267-4CA1-A7E0-F90E0D09022E</gtr:id><gtr:firstName>Gwo-Tzer</gtr:firstName><gtr:surname>Ho</gtr:surname><gtr:orcidId>0000-0002-6014-372X</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701898"><gtr:id>CF2D4F02-E05A-44E0-B656-7BC360A39408</gtr:id><gtr:title>Modulation of P-glycoprotein 170 function as a therapeutic target in ulcerative colitis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701898</gtr:grantReference><gtr:abstractText>Ulcerative colitis is a common and chronic inflammatory disease affecting the large intestines. The cause of the illness is unknown, although there is strong evidence that both genetic and environmental factors contribute. Current treatment is unsatisfactory, relying on toxic drugs which suppress the immune system. Recently studies from our laboratory suggest that variations in a gene (MDR-1) that codes for a pump that transports foreign particles out of cells might be involved in causing the disease. I plan to study this in detail in this project. I will manipulate the levels of gene and pump levels in mouse models of ulcerative colitis and human gut cells and determine if this influences the level of gut inflammation. I will use the latest gene manipulation technology to change the levels of gene expression and to study gene changes that occurs after PgP manipulation. This will also provide the opportunity to study how PgP interact with other mechanisms of gut defence and the immune system. I will test how PgP respond to fragments of bacteria and chemicals which provoke inflammation. These experiments provide the basis of a possible new mechanism for how UC develops and importantly, the development of a future treatment.</gtr:abstractText><gtr:technicalSummary>Background: Ulcerative colitis (UC) is a common relapsing inflammatory disease affecting 250/100 000 individuals in UK. The morbidity associated with active UC is high, 15% develop severe disease, of which 30% will require emergency surgery. There is compelling evidence for the multidrug resistance gene 1 (MDR1) in the pathogenesis of UC. MDR1 encodes P-glycoprotein 170 (PgP), a transmembrane ATP-dependent efflux protein which drives the transport of a diverse range of molecules to the outside of cells. The MDR1 gene maps to chromosome 7q22, a susceptibility locus for IBD and germline variations of this gene are strongly associated with UC (haplotypic association, p&amp;lt;0.001). This is further strengthened by significantly lower PgP expression on intestinal epithelium in UC (basal and inflamed states; p&amp;lt;0.001). The MDR1 knock-out murine model develops colitis.
Aims: I will study the contribution of PgP to intestinal inflammation and if modulation of PgP expression can result in improvement. I will question if changes in PgP expression in vivo modifies intestinal inflammation, and if in vitro changes of protein expression on intestinal epithelial cells alter cell response to inflammatory stimuli.
Experimental designs: The effect of modulating PgP expression on intestinal inflammation will be examined by using established inducers and inhibitors in 2 animal models (chronic HLA B27/?2-microglobulin transgenic and acute DSS-colitis models). These represent inflammation induced by bacterial flora and hapten (biochemical inflammation) respectively. I will perform comparative analyses of histological and disease parameters of inflammation; and determine the cytokine profile and degree of bacterial translocation in PgP high and low states. I hypothesise that the upregulation of PgP will lead to the improvement of colitis, which will worsen in specific PgP inhibition. To provide relevance to human disease and to further elucidate the underlying mechanism of PgP-mediated protection, I will investigate the effects of PgP modulation on cell response after exposure to pro-inflammatory cytokines and pathogen associated molecular patterns stimulation in human intestinal epithelial cell line (LS180). This will be done using whole genome expressions approach in PgPhigh and PgPnull state following stable knock-down of the MDR1 gene. Confirmatory work will be performed on short-term culture of intestinal epithelial cells of controls and newly-diagnosed (treatment na&amp;iuml;ve) UC patients.
Potential outcomes: The proposed study will be the first in-depth study in the role of PgP in intestinal inflammation and a direct translation from genetic to molecular function. Since PgP function can be manipulated, there is distinct scope for translation work.</gtr:technicalSummary><gtr:fund><gtr:end>2013-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>909783</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>Investigating the function of calprotectin in ulcerative colitis</gtr:description><gtr:id>75BEB1D4-119A-47E5-9C2B-25FB9A098D17</gtr:id><gtr:impact>1 current grant application under review.
1 joint PhD student.
Now developing the foundations of a senior clinical fellowship application.</gtr:impact><gtr:outcomeId>JiFLxM4n7da-1</gtr:outcomeId><gtr:partnerContribution>We are developing novel methods to target and monitor intestinal inflammation in mouse models. This is a collaboration with a premier group with international reputation in this area.</gtr:partnerContribution><gtr:piContribution>I am providing intellectual input and hands-on expertise in mouse modelling of intestinal inflammation. I am testing novel applications and ideas in the field of inflammatory bowel disease.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of East Anglia</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Faculty of Health and Life Sciences</gtr:department><gtr:description>The role of ATG16L1 gene and gut epithelial autophagy</gtr:description><gtr:id>59AA1DB4-BBFA-4718-AF16-51F504709CB4</gtr:id><gtr:impact>Current MRC project grant proposal in progress.</gtr:impact><gtr:outcomeId>NiDe1y3frKa-1</gtr:outcomeId><gtr:partnerContribution>UEA has generated the first gut-specific ATG16L1 mouse-deficient model. ATG16L1 is a top genetic 'hit' in Crohn's disease.</gtr:partnerContribution><gtr:piContribution>We provide technical and intellectual input into mouse modelling of gut inflammation and ultrastructural analysis of epithelial organelle morphology. In addition, access to human samples of IBD.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Cardiovascular Science</gtr:department><gtr:description>Characterisation of gut mucosal bioenergetics in IBD</gtr:description><gtr:id>4ABB4950-2876-4EBE-B790-F987B56D9388</gtr:id><gtr:impact>This has led to an application to Wellcome Trust ISSF2 and Student Vacation applications in 2016.
Publication of a paper in Mucosal Immunology: MDR1-deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation. (in press, March 2017)</gtr:impact><gtr:outcomeId>56d4766d661483.02609047-1</gtr:outcomeId><gtr:partnerContribution>Professor Nik Morton (Chair of Molecular Metabolism, University of Edinburgh) is providing Seahorse analysis into this primary gut study,</gtr:partnerContribution><gtr:piContribution>We are characterising the bioenergetics of gut mucosal IBD using the Seahorse XF Platform.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Chiba University</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Investigating primary gut mitochondrial function in vivo</gtr:description><gtr:id>7E5F2004-A090-4F2D-A213-514519F9B791</gtr:id><gtr:impact>Not yet.</gtr:impact><gtr:outcomeId>Q8ZAL9RPyEo-1</gtr:outcomeId><gtr:partnerContribution>The generation of epithelial-specific SOD2 deficient model will be the first primary mitochondrial gut knock-out model and will form the major basis of our current work/future grant.</gtr:partnerContribution><gtr:piContribution>Chiba University provided the SOD2-floxed mouse model for my studies into gut mitochondrial function.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>Translational investigation of kynurenine 3-monooxygenase blockade as a novel therapeutic strategy in inflammatory bowel disease</gtr:description><gtr:id>73CA389B-084C-48CE-8EF3-94728B0923A6</gtr:id><gtr:impact>In progress.</gtr:impact><gtr:outcomeId>VHudinWoHgQ-1</gtr:outcomeId><gtr:partnerContribution>Our collaborators have a pipeline award from Drug Discovery Unit, GSK including some novel compounds which will be tested in this project. They are now screening our IBD plasma samples and results are awaited.</gtr:partnerContribution><gtr:piContribution>Collaboration to investigate new inflammatory pathway in inflammatory bowel disease. We provide the mouse colitis models for this current program. We are now providing human IBD plasma samples to screen for KMO metabolite profiles.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wolfson Centre for Personalised Medicine</gtr:department><gtr:description>Investigation into the role of ABCB5 in determining clinical outcome glucocorticoid therapy in paediatric IBD</gtr:description><gtr:id>41B2FB96-9379-455E-AC89-4DEEE2DA30C0</gtr:id><gtr:impact>Wellcome Trust Training Fellowship - joint application (awaiting outcome).</gtr:impact><gtr:outcomeId>pmxEzn1QETz-1</gtr:outcomeId><gtr:partnerContribution>Functional assay of ABCB5 efflux function in cellular subsets in human blood and gut biopsies.</gtr:partnerContribution><gtr:piContribution>Clinical research into the paediatric IBD cohort in Edinburgh university.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Muhimbili University of Health and Allied Sciences</gtr:collaboratingOrganisation><gtr:country>Tanzania, United Republic of</gtr:country><gtr:department>Department of Microbiology and Immunology</gtr:department><gtr:description>The role of innate epithelial host response to intestinal microbiota in inflammatory bowel disease</gtr:description><gtr:id>C2CF15AF-8EFD-4370-B98B-B2FF824CCF0F</gtr:id><gtr:impact>Successful award of ECCO grant. Work remains in progress.</gtr:impact><gtr:outcomeId>J2JvpSFNyXo-1</gtr:outcomeId><gtr:partnerContribution>My collaborators are continuing to provide animals, intellectual support and further data to support my current work. In addition, we are jointly working on a project that investigate the role of NOD2 protein in macrophage bacterial killing (as a co-lead investigator).</gtr:partnerContribution><gtr:piContribution>We have provided intellectual and human resource to the development of new in vivo modelling techniques in intestinal inflammation (including the generation of new animal models).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Clinical Cancer Medicine</gtr:department><gtr:description>The role of ABCB5 gene in corticosteroid resistance in IBD</gtr:description><gtr:id>F81F2ADA-C83D-40C8-BF60-4C3BCB55DC45</gtr:id><gtr:impact>We have identified a major novel transport mechanisms for drug substrate particularly corticosteroids, mediated by ABCB5. These findings are not yet published.</gtr:impact><gtr:outcomeId>ZvYC6SE9MMe-1</gtr:outcomeId><gtr:partnerContribution>The shared development of new functional assays of epithelial transport activity (ABCB5), a close homolog to ABCB1/MDR1, the gene of primary interest in this MRC Clinician Scientist Award.</gtr:partnerContribution><gtr:piContribution>I am the investigator that discovered a group of genes that are linked to pharmacogenetic variation of steroid response from my discovery cohort of patients with inflammatory bowel disease. Provided intellectual input and supervision. Current named co-applicant in this project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>Investigating the translational importance of intestinal mitochondrial damage associated molecular patterns (mtDAMPs) in inflammatory bowel disease (IBD).</gtr:description><gtr:id>93C01095-3E29-41A1-9BB5-2DBC1718CAD7</gtr:id><gtr:impact>In progress. Awaiting outcome of current grant submission to Crohn's and Colitis UK foundation.</gtr:impact><gtr:outcomeId>LBiGQJsmXyf-1</gtr:outcomeId><gtr:partnerContribution>Provide technical expertise in mitochondria markers within circulation of inflammatory bowel disease patients.</gtr:partnerContribution><gtr:piContribution>Collaboration with Professor Adriano Rossi's group in MRC CIR. Currently, provide biological material from patients with inflammatory bowel disease to complement in vivo work.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>National Radio Broadcast in Australia</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8CB7E436-9543-4D16-A6EB-4A602B856028</gtr:id><gtr:impact>My research fellow, based on work that he has done here in Edinburgh was interviewed by Dr Norman Swan, on National Australian Radio December 2015.</gtr:impact><gtr:outcomeId>56d479e2216fd4.32810571</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to intermediate academics and clinical lecturers.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EBC4EC96-C7AB-49DE-920C-3A69D51620FD</gtr:id><gtr:impact>Around 15 Edinburgh Clinical Academic Track lecturers attended my talk about my current work and this stimulated quite fruitful discussions regarding their own career paths and choices.

N/A</gtr:impact><gtr:outcomeId>544cc93eae9247.97783472</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National lead newspaper article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>731A7E2E-1E39-48CF-8399-AD09CF0DBE23</gtr:id><gtr:impact>National Malaysian lead article in the daily broadsheet newspaper about my current work funded by MRC.

Numerous inquires by national governmental funding agencies and medical students (UK and Malaysia).</gtr:impact><gtr:outcomeId>FTLsVq8TCC2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Image of the Month</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>EE873C9F-8C47-469A-B2CD-9A6D02254793</gtr:id><gtr:impact>My work was featured at MRC Centre for Inflammation Research, Image of the Month in December 2015, showing striking pictures of segmented filamentous bacteria on mouse gut surface using scanning electron microscopy.</gtr:impact><gtr:outcomeId>56d47a6fa53d51.31472345</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Life as a clinician scientist to Primary School audience</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>77DF2E0E-0801-4258-A1BA-4AE3D4B11510</gtr:id><gtr:impact>Around 75 students attended my talk and I was able to give many face to face discussions about my career as a clinician scientist.

The school asked for future engagement talks in the senior school.</gtr:impact><gtr:outcomeId>544cc89165ca16.18936281</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Editorial interview by American Journal of Gastroenterology on my article, 'Precision Medicine in Inflammatory Bowel Disease'.</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C7B06639-FA2A-44D1-8F1C-EE47B1415A21</gtr:id><gtr:impact>I gave an 20 minute interview on the future directions in Precision Medicine in Inflammatory Bowel Disease, interviewed by Dr Brian Lacy - chief editor of American Journal of Gastroenterology. This interview was directed towards the general audience in particular all stake holders of research, health care and individuals with inflammatory bowel disease. The audience coverage was international, mostly USA and Europe. The podcast remains available in American Journal of Gastroenterology and iTunes.</gtr:impact><gtr:outcomeId>58c130d25a64d1.99475133</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>https://gi.org/physician-resources/podcasts/the-american-journal-of-gastroenterology-author-podcasts/ho/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio Interview by Australian radio ABC 'The Health Report' on Inflammatory Bowel Disease</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>237819F7-F8E7-41FE-B36B-DA98C867CABF</gtr:id><gtr:impact>Radio interview by Dr Ray Boyapati, MD Researcher under my supervision on the outcomes of Inflammatory Bowel Disease and our research in Edinburgh. The interview was broadcasted in Australian public radio, on the health program 'The Health Report'.</gtr:impact><gtr:outcomeId>58c1344aed0d72.71827835</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.ed.ac.uk/inflammation-research/news-events/archive/2015/researcher-speaks-on-australian-radio</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Vacation Scholarship</gtr:department><gtr:description>Wellcome Trust Vacation Scholarship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>202597/Z/16/Z</gtr:fundingRef><gtr:id>7AC2DB9D-F2D8-46CC-9970-2AC5401AD695</gtr:id><gtr:outcomeId>58c12e2cccc204.44963307</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>8000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Crohn's and Colitis UK</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Crohn's and Colitis UK</gtr:fundingOrg><gtr:fundingRef>M16-1</gtr:fundingRef><gtr:id>3F537017-A017-4722-AD2C-64DA93CECA77</gtr:id><gtr:outcomeId>58c12d96b01c06.55375419</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Medical Research Society</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Society</gtr:fundingOrg><gtr:fundingRef>Vac-982-2016</gtr:fundingRef><gtr:id>B6EC19B0-E2E6-458C-86ED-AA81C6DDD216</gtr:id><gtr:outcomeId>58c12ec4272157.78586807</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2016-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of North Carolina studentship award</gtr:description><gtr:end>2010-08-02</gtr:end><gtr:fundingOrg>University of North Carolina at Chapel Hill</gtr:fundingOrg><gtr:id>2C5EC69A-D5C6-4734-9167-D94778963CE6</gtr:id><gtr:outcomeId>eqZvzmwWuBr0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant: Investigation of ABCB5 in corticosteroid resistance in inflammatory bowel disease</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>National Association for Colitis and Crohn?s Disease (NACC)</gtr:fundingOrg><gtr:id>840EC3FB-E3A8-49F6-8964-41F47BD82E45</gtr:id><gtr:outcomeId>XnN8kWTyv9n0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Award: Development of an integrated gene expression system in the intestinal epithelium</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>European Crohn's and Colitis Organisation (ECCO)</gtr:fundingOrg><gtr:id>4DC648E8-59A8-4688-AAC4-E8401B34B714</gtr:id><gtr:outcomeId>Nc15hqScrZU0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Edinburgh GI Trustees Fund</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>University of Edinburgh</gtr:fundingOrg><gtr:id>8C106B7C-AEED-450C-98A1-588779B40C62</gtr:id><gtr:outcomeId>56d4781f64e6b9.46636627</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Translational Project Grant (ETMR CSO): Improving outcome of acute severe ulcerative colitis (OASIS)</gtr:description><gtr:end>2012-05-02</gtr:end><gtr:fundingOrg>Chief Scientist Office (CSO)</gtr:fundingOrg><gtr:id>1155E2FB-0631-4B49-B74E-F6540F3528BB</gtr:id><gtr:outcomeId>N7kwv9GN5DJ0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British Society of Gastroenterology IBD Guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>295D8D52-CCD1-4DA3-ABCF-FBC27A5779AE</gtr:id><gtr:impact>My involvement at the interface of science and clinical practice has led to this role in forming new national guidelines in inflammatory bowel disease.</gtr:impact><gtr:outcomeId>nFUZwFmX5ix</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>British Society of Gastroenterology Academic Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6969B3AF-3253-4D11-9C06-39E1108EE0B3</gtr:id><gtr:outcomeId>MrJfFvNE97W</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>From my experience acquired from University of North Carolina, I have now established an independent program of animal colitis work in Edinburgh University. This has led to multiple new lines of collaborative work within the MRC Centre for Inflammation Research in Edinburgh.</gtr:description><gtr:id>79F85CBB-A6AD-45F6-9EFF-A8CBB0E42463</gtr:id><gtr:impact>Due to my expertise, 2 submitted grant applications, 1 PhD studentship, expansion of the Edinburgh GI Unit to cover epigenetics work by current head of department, 1 academic-industrial collaboration with Taconic Artemis.

Following on, now extended collaborations to involve a number of research groups in Edinburgh, studying gut inflammation (Julia Dorin - MRC Human Genetics Unit, John Savill - MRC Centre for Inflammation, Professor Mark Arend, CRUK Edinburgh.</gtr:impact><gtr:outcomeId>QHAvZRmEFgM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Project Licence for animal colitis modelling in Edinburgh</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>In collaboration with Taconic - access to novel humanised mouse models for investigation of new targets in colitis.</gtr:description><gtr:id>7BE0531F-8043-4445-B5A7-437C3DE72271</gtr:id><gtr:impact>Significant expansion of current fellowship work.</gtr:impact><gtr:outcomeId>Evh4y4FMLKj</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Humanised mouse models for colitis - to investigate therapeutic modulation of drug targets</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I generated a combined epithelial and immunologic murine colitis model - by crossing MDR1-/- and IL10-/- C57/BL6 strain.</gtr:description><gtr:id>DCC202A2-3F09-4F5C-BC99-4DC5CA4F9A38</gtr:id><gtr:impact>This is an entirely new animal model and is under current investigation.</gtr:impact><gtr:outcomeId>AAwYznwnTLr</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Creation of new murine double knock-out line (MDR1-IL10).</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I successful generated 2 new stable knockdown MDR1 cell lines.</gtr:description><gtr:id>490605D5-CDBF-4B09-95B0-83DCD930EBD9</gtr:id><gtr:impact>This has provided a reliable in vitro platfrom to study the effects of MDR1 knockdown on epithelial barrier function.</gtr:impact><gtr:outcomeId>UqqwmDuaEAC</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Long term MDR1 knockdown intestinal epithelial line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>I have set up villin-cre recombinase mouse line to enable gut specific gene deletion models.</gtr:description><gtr:id>1CA0CD82-0B3F-41BB-B733-9928AC7D610E</gtr:id><gtr:impact>Not available yet.</gtr:impact><gtr:outcomeId>544ccc5f2e2d57.80873236</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Creation of gut specific gene deletion models in Edinburgh</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>576091ED-B720-48D6-812E-5A332D9614CE</gtr:id><gtr:title>Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64f42b266fd11aa87e2c88a384ee9d26"><gtr:id>64f42b266fd11aa87e2c88a384ee9d26</gtr:id><gtr:otherNames>Ho GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>pm_13094_14_19262524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F31159E-3B24-4DA0-84E4-3ABB4BF1D79F</gtr:id><gtr:title>Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008).</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64f42b266fd11aa87e2c88a384ee9d26"><gtr:id>64f42b266fd11aa87e2c88a384ee9d26</gtr:id><gtr:otherNames>Ho GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_13094_14_19183339</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A07DF390-56D8-4106-AFBF-81C1391CCB8E</gtr:id><gtr:title>Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7cfe472cce65a6e4c1409d62261cbc1"><gtr:id>a7cfe472cce65a6e4c1409d62261cbc1</gtr:id><gtr:otherNames>Kalla R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>58c12bdc7c3c97.76520591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41F33D3E-BF8A-4CBD-8145-0409837C5928</gtr:id><gtr:title>Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study.</gtr:title><gtr:parentPublicationTitle>Inflammatory bowel diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c1396e262f01d61d4d04461debba360"><gtr:id>3c1396e262f01d61d4d04461debba360</gtr:id><gtr:otherNames>Andersen V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0998</gtr:issn><gtr:outcomeId>pm_13094_24_20803508</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63A51193-1B36-43DC-8650-465A195D2BC0</gtr:id><gtr:title>Guidelines for the management of inflammatory bowel disease in adults.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5872a5fbb017c81d000ff8540547d87a"><gtr:id>5872a5fbb017c81d000ff8540547d87a</gtr:id><gtr:otherNames>Mowat C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56d47e87648269.62019534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>888C6BBF-DA45-4EC0-9133-B9A72B2AC081</gtr:id><gtr:title>Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases.</gtr:title><gtr:parentPublicationTitle>F1000Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b1a25bedef401550366563cc3c49fc"><gtr:id>28b1a25bedef401550366563cc3c49fc</gtr:id><gtr:otherNames>Boyapati RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2046-1402</gtr:issn><gtr:outcomeId>58c12af96ae683.62722101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB54199F-5918-4381-9905-A5F6FF08D8F7</gtr:id><gtr:title>Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33800cbdd8ec2b7e624dd14dad808264"><gtr:id>33800cbdd8ec2b7e624dd14dad808264</gtr:id><gtr:otherNames>Hare NC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_13094_24_22240391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFB09FE8-93B1-42B4-B37D-1979946BCB5C</gtr:id><gtr:title>Pathogenesis of Crohn's disease.</gtr:title><gtr:parentPublicationTitle>F1000prime reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d303a6716833659b362d79806b3d7355"><gtr:id>d303a6716833659b362d79806b3d7355</gtr:id><gtr:otherNames>Boyapati R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2051-7599</gtr:issn><gtr:outcomeId>56d474519bc1c8.88437399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>612B34E9-6199-4E26-B916-086025FCEB62</gtr:id><gtr:title>Analysis of germline GLI1 variation implicates hedgehog signalling in the regulation of intestinal inflammatory pathways.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bd368253fec639b465fd164d29cb2ba"><gtr:id>2bd368253fec639b465fd164d29cb2ba</gtr:id><gtr:otherNames>Lees CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>pm_13094_14_19071955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42C4DA79-F68C-4EEC-A0BA-5F9ADDAAAE9C</gtr:id><gtr:title>Biomarkers in Search of Precision Medicine in IBD.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b1a25bedef401550366563cc3c49fc"><gtr:id>28b1a25bedef401550366563cc3c49fc</gtr:id><gtr:otherNames>Boyapati RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>58c12bab7e5712.72953080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89E9011A-943E-45A6-AA63-B0B01CDA1849</gtr:id><gtr:title>Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/370760c2b2beee5cc61a02c9e4c3e85c"><gtr:id>370760c2b2beee5cc61a02c9e4c3e85c</gtr:id><gtr:otherNames>Noble CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>pm_13094_14_18523026</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1B06ED4-B559-4E63-82D6-C45CD355B61F</gtr:id><gtr:title>Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b1a25bedef401550366563cc3c49fc"><gtr:id>28b1a25bedef401550366563cc3c49fc</gtr:id><gtr:otherNames>Boyapati RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>56d479020a78b2.52825840</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75803ED6-84E8-4F79-B91D-8920BE4EF2E9</gtr:id><gtr:title>Editorial: what can be done when infliximab stops working in ulcerative colitis?</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b1a25bedef401550366563cc3c49fc"><gtr:id>28b1a25bedef401550366563cc3c49fc</gtr:id><gtr:otherNames>Boyapati RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>56d47451d85187.91190101</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69F5E150-A76E-4B6D-8B5B-A7F0E734E4BE</gtr:id><gtr:title>The use of adalimumab in the management of refractory Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64f42b266fd11aa87e2c88a384ee9d26"><gtr:id>64f42b266fd11aa87e2c88a384ee9d26</gtr:id><gtr:otherNames>Ho GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_13094_14_18081730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>268DE224-9CE0-4C8B-A676-C9B9C0BA19F8</gtr:id><gtr:title>Outcomes of the rectal remnant following colectomy for ulcerative colitis.</gtr:title><gtr:parentPublicationTitle>Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df60277edda9a78d55ba1ce2700dd0b5"><gtr:id>df60277edda9a78d55ba1ce2700dd0b5</gtr:id><gtr:otherNames>Brady RR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1462-8910</gtr:issn><gtr:outcomeId>pm_13094_14_17302914</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04BBC2AE-02CD-4C11-B3A5-FC4316AAE7CB</gtr:id><gtr:title>MDR1 deficiency impairs mitochondrial homeostasis and promotes intestinal inflammation.</gtr:title><gtr:parentPublicationTitle>Mucosal immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64f42b266fd11aa87e2c88a384ee9d26"><gtr:id>64f42b266fd11aa87e2c88a384ee9d26</gtr:id><gtr:otherNames>Ho GT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1933-0219</gtr:issn><gtr:outcomeId>5a31dab9029755.84573330</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4BFB0BBD-F0F3-4643-9B84-C38BAFBD0811</gtr:id><gtr:title>A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/58e9b7843c867fa71473bb98977691f6"><gtr:id>58e9b7843c867fa71473bb98977691f6</gtr:id><gtr:otherNames>Russell RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_13094_24_21342211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0A587AA-646B-410E-94C3-8B9E084DE270</gtr:id><gtr:title>The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bd368253fec639b465fd164d29cb2ba"><gtr:id>2bd368253fec639b465fd164d29cb2ba</gtr:id><gtr:otherNames>Lees CW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>pm_13094_14_19132970</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC2EB65E-3120-47F2-801A-F0812EBF82ED</gtr:id><gtr:title>Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28b1a25bedef401550366563cc3c49fc"><gtr:id>28b1a25bedef401550366563cc3c49fc</gtr:id><gtr:otherNames>Boyapati RK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>58c12b736f5c65.94844875</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33FCE21C-8ACF-4544-9DCA-F711B41117AC</gtr:id><gtr:title>Integrative epigenome-wide analysis demonstrates that DNA methylation may mediate genetic risk in inflammatory bowel disease.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be7f3c9c818fb8f7c8a3e8507c421eed"><gtr:id>be7f3c9c818fb8f7c8a3e8507c421eed</gtr:id><gtr:otherNames>Ventham NT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c12b389a4025.35700318</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701898</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>